January 2011
Worldwide Biotech;Jan2011, Vol. 23 Issue 1, p2
Trade Publication
This article reports on the decision of the Danish Medicines Agency of Denmark to approve the Marketing Authorization Application (MAA) for SUMAVEL DosePro (sumatriptan injection) Needle-Free Delivery System from Zogenix Inc. Desitin Pharmaceuticals GmbH serves as the company's partner in the launch of the product. Roger L. Hawley, chief executive officer (CEO) and director of Zogenix, looks forward to the commercial launch of the product in the European Union (EU).


Related Articles

  • ZOGENIX BEGINS PROMOTION OF MIGRANAL NASAL SPRAY.  // Biotech Equipment Update;Sep2013, Vol. 21 Issue 9, p4 

    The article offers information on the promotion of Migranal Nasal Spray in the U.S. by Zogenix, specialty pharmaceutical company, which has a co-promotion agreement with Valeant Pharmaceuticals North America LLC, multinational specialty pharmaceutical company. It presents the views of Roger L....

  • Zohydro faces a possible competitor. Weinstein, Deborah // Medical Marketing & Media;Apr2014, Vol. 49 Issue 4, p11 

    The article reports on the approval issues facing hydrocodone medication Zohydro, made by Zogenix Inc.

  • Did "pay-to-play" confab help Zohydro approval? Dickinson, James G. // Medical Marketing & Media;Apr2014, Vol. 49 Issue 4, p28 

    The article reports on the influence of the meeting between pharmaceutical industry executives and the U.S. Food and Drug Administration (FDA) officials on the agency's approval of Zogenix Inc.'s Zohydro prescription painkiller.

  • EU panel says yes to key drugs. Investor's Business Daily // Investors Business Daily;9/28/2015, pA02 

    The article reports on the endorsement of primary drugs for approval by the European Union Committee for Medicinal Products for Human Use in 2015.

  • Pipeline.  // Medical Marketing & Media;Mar2015, Vol. 50 Issue 3, p13 

    The article offers news briefs related to the pharmaceutical industry on topics including approval of the drugs Lenvima from Eisai, Natpara from NPS Pharma, and the Zohydro ER painkiller from Zogenix Inc.

  • Financings roundup.  // Medical Device Daily;7/20/2009, Vol. 13 Issue 137, p3 

    The article reports on the approval of Zogenix's Sumavel DosePro sumatriptan injection needle-free delivery system by Aradigm. Under the terms of the deal, Aradigm receives the right for a $4 million milestone payment upon any sale made in the U.S. and other countries. The device utilizes the...

  • Startup Works on Getting Injectable Migraine Treatment to Market. Chambers, Heather // San Diego Business Journal;8/24/2009, Vol. 30 Issue 34, p3 

    The article focuses on the release of the Sumavel DosePro by pharmaceutical firm Zogenix Inc. in the U.S. in 2009. The company invested 100 million U.S. dollars on the drug with the hope that it would result significant profits. Chief executive officer (CEO) Roger Hawley believes that the...

  • Delays in New Drug Applications in Japan and Industrial R&D Strategies. Hirai, Y.; Kinoshita, H.; Kusama, M.; Yasuda, K.; Sugiyama, Y.; Ono, S. // Clinical Pharmacology & Therapeutics;Feb2010, Vol. 87 Issue 2, p212 

    The gap between Japan and both the United States (US) and the European Union (EU) with regard to access to new drugs is becoming a major issue in Japan. We analyzed the time lags involved in new drug application (NDA) and biological license application submissions in Japan, the US, and the EU in...

  • Too few patients are studied for long-term-use drug approvals.  // Reactions Weekly;03/23/2013, Issue 1445, p2 

    The article reports that according to the results of a database analysis of all new drugs approved in the European Union (EU) during 2000-2010, all chronic-use drugs were not evaluated in enough patients before their approval.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics